| 1 |
Mulrooney-Cousins PM, Michalak TI. Asymptomatic Hepadnaviral Persistence and Its Consequences in the Woodchuck Model of Occult Hepatitis B Virus Infection. J Clin Transl Hepatol. 2015;3:211-219. [PMID: 26623268 DOI: 10.14218/jcth.2015.00020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 2 |
Saccà F, Pane C, De Rosa A, Matarazzo M, Brescia Morra V. Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection. Neurol Sci 2017;38:501-2. [DOI: 10.1007/s10072-016-2726-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 3 |
Yanovsky RL, McLeod M, Ahmed AR. Treatment of pemphigus vulgaris: part 1 - current therapies. Expert Rev Clin Immunol 2019;15:1047-60. [PMID: 31566020 DOI: 10.1080/1744666X.2020.1672535] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 4 |
Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol 2016; 22(28): 6444-6455 [PMID: 27605880 DOI: 10.3748/wjg.v22.i28.6444] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 5 |
Von Drygalski A, Giermasz A, Castaman G, Key NS, Lattimore S, Leebeek FWG, Miesbach W, Recht M, Long A, Gut R, Sawyer EK, Pipe SW. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv 2019;3:3241-7. [PMID: 31698454 DOI: 10.1182/bloodadvances.2019000811] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 6 |
Talotta R, Atzeni F, Sarzi Puttini P. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report. BMC Pharmacol Toxicol 2016;17:17. [PMID: 27098382 DOI: 10.1186/s40360-016-0060-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 7 |
Cobb BR, Valsamakis A. Chronic Hepatitis B, C, and D. Microbiol Spectr 2016;4. [PMID: 27726758 DOI: 10.1128/microbiolspec.DMIH2-0025-2015] [Reference Citation Analysis]
|
| 8 |
Tang SC, Wong AK, Mak SK. Clinical practice guidelines for the provision of renal service in Hong Kong: General Nephrology. Nephrology (Carlton) 2019;24 Suppl 1:9-26. [PMID: 30900340 DOI: 10.1111/nep.13500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 9 |
Soriano V, Labarga P, de Mendoza C, Peña JM, Fernández-montero JV, Benítez L, Esposito I, Barreiro P. Emerging Challenges in Managing Hepatitis B in HIV Patients. Curr HIV/AIDS Rep 2015;12:344-52. [DOI: 10.1007/s11904-015-0275-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 10 |
Alexanian D, Birg A, Volpicelli N, Glass J, McCarthy D. Latent Hepatitis Virus Reactivation Due to Drug Reaction: DRESSed to Kill? Dig Dis Sci. 2018;63:1143-1147. [PMID: 29594978 DOI: 10.1007/s10620-018-5028-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 11 |
Fang J, Li W, Tan M, Chen W, Zhang C, Wang W, Xu Q, Guo X. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation. Int Urol Nephrol 2018;50:1653-60. [PMID: 29644524 DOI: 10.1007/s11255-018-1867-0] [Reference Citation Analysis]
|
